Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P150038/S043

Exablate Model 4000 System

Insightec · Decision date Jan 28, 2026

FDA DECISIONP150038/S043

What did the FDA decide?

FDA records P150038/S043 as a supplement to PMA P150038, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jan 28, 2026.

FDA approval order statement

a change in Exablate 4000 Digital Control and Acquisition board (DCA) testing procedure
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Neurology
Decision date
Jan 28, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P150038/S043
Regulatory pathway
PMA supplement
Applicant
Insightec
Product code
POH
Decision code
OK30
Decision date
Jan 28, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: MR-guided focused ultrasound system.

Applicant
Insightec
Product code
POH
FDA device class
3

For the original device and its historical approval scope, see PMA P150038. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P150038/S043 received

    Application receipt date recorded by FDA.

  2. P150038/S043 · FDA decision

    30-Day Notice

  3. P150038/S042 · Related supplement

    Exablate Model 4000 Type 1.0 and 1.1 (Exablate Neuro; Exablate Prime)

  4. P150038/S044 · Related supplement

    Exablate Model 4000 System

Timeline entries are records held by MedtechLedger for P150038. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P150038

Product / regulatory recordCompanyPathwayDecision dateSource
EXABLATEP150038
InsightecPMA approvalJul 11, 2016FDA
InsightecPMA supplementMar 5, 2026FDA
EXABLATEP150038/S041
InsightecPMA supplementMar 23, 2026FDA
InsightecPMA supplementSep 16, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Insightec

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
5 Nahum Heth St., Tirat Carmel, 39120

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records